Clinical and Ultrasonographic Evaluation of Lower-extremity Vein Thrombosis in Behcet Syndrome

An Observational Study

Emire Seyahi, MD, Osman Serdal Cakmak, MD, Burcin Tutar, MD, Caner Arslan, MD, Attila Suleyman Dikici, MD, Necdet Sut, PhD, Fatih Kantarcı, MD, Hasan Tuzun, MD, Melike Melikoglu, MD, and Hasan Yazici, MD

Abstract: Vascular involvement can be seen in up to 40% of patients with Behcet syndrome (BS), the lower-extremity vein thrombosis (LEVT) being the most common type. The aim of the current study was to compare venous Doppler findings and clinical features between BS patients with LEVT and control patients diagnosed as having LEVT due to other causes.

All consecutive 78 patients (71 men, 7 women; mean age 38.6 ± 10.3 years) with LEVT due to BS and 50 control patients (29 men, 21 women; mean age 42.0 ± 12.5 years) who had LEVT due to other causes, or idiopathic, were studied with the help of a Doppler ultrasonography after a detailed clinical examination. Patterns of venous disease were identified by cluster analyses. Clinical features of chronic venous disease were assessed using 2 classification systems. Venous claudication was also assessed.

Patients with BS were more likely to be men, had significantly earlier age of onset of thrombosis, and were treated mainly with immunosuppressives and less frequently with anticoagulants. Furthermore, they had significantly more bilateral involvement, less complete recanalization, and more frequent collateral formation. While control patients had a disorganized pattern of venous involvement, BS patients had a contiguous and symmetric pattern, involving all deep and superficial veins of the lower extremities, with less affinity for crural veins. Clinical assessment, as measured by the 2 classification systems, also indicated a more severe disease among the BS patients. In line, 51% of the BS patients suffered from severe post-thrombotic syndrome (PTS) and 32% from venous claudication, whereas these were present in 8% and 12%, respectively, among the controls. Among BS patients, a longer duration of thrombosis, bilateral femoral vein involvement, and using no anticoagulation along with immunosuppressive treatment when first diagnosed were found to be associated independently with severe PTS.

INTRODUCTION

Vascular involvement can be seen in up to 40% of patients with Behcet syndrome (BS). Lower-extremity vein thrombosis (LEVT) is the most common type of involvement. It generally starts within few years of disease onset and tends to precede major vessel involvement at other sites. Similar to the other manifestations of BS, it runs a relapsing course. Apart from 2 previous studies from our group, detailed Doppler ultrasonographic evaluation of LEVT, along with its clinical associations, has not been available.

The post-thrombotic syndrome (PTS) is a common chronic complication of LEVT with chronic pain, leg edema, and stasis ulcerations. We had the impression that LEVT due to BS had a more severe course, resulting in a higher frequency of PTS than is the case with garden-variety LEVT. This comparison has not formally been made.

Thus, the objective of the current study among BS patients with known LEVT, along with control patients diagnosed as having LEVT due to other causes, was to compare the venous Doppler ultrasonography (USG) findings and their association with the clinical course between the 2 groups, with special emphasis on development of PTS.

PATIENTS AND METHODS

We studied consecutive BS patients with LEVT who attended the dedicated BS outpatient clinic at the Cerrahpaşa Medical Faculty of University of Istanbul, and control patients who had LEVT due to other causes who attended the outpatient clinic of the Department of Cardiovascular Surgery of the same institution. Both patients and controls were consecutive...
outpatients seen within the same time period. All BS patients had fulfilled the International Study Group Criteria. BS signs and symptoms were sought in all controls, and only those patients who did not meet the criteria for BS were included in the study. All patients in the control group underwent a detailed investigation for thrombophilia; however, such an investigation was not done in the routine work-up for BS.

By definition, all patients and the controls had a documented thrombotic event in the lower extremities. LEVT was defined as any (acute, subacute, or chronic) thrombotic event in any (superficial or deep) lower-extremity vein demonstrated by Doppler USG. The veins involved as documented on the first available Doppler USG were also recorded. A few patients with only venous insufficiency from either group were excluded.

Lower-extremity Doppler USG Assessment

All patients and controls were reanalyzed using color Doppler USG in the Radiology Department, by a radiologist who was blinded to the clinical diagnosis of the patients and controls. In each patient, a total of 16 superficial and deep veins in both legs were assessed for the presence or absence of obstruction, recanalization, reflux, and collaterals. These were as follows: iliac vein, common femoral vein (CFV), deep femoral vein (DFV), superficial femoral vein (SFV), popliteal vein (PV), vena saphena magna (VSM), vena saphena parva (VSP), and crural veins. USG examinations were completed within 2 weeks following the clinical examination.

Clinical Assessment

The age at first thrombotic event was obtained from the charts. Demographic and clinical characteristics, drugs used after the diagnosis of thrombosis and those currently used, along with smoking and working status, were surveyed by a standardized questionnaire (Appendix 1, http://links.lww.com/MD/A482). Clinical features of chronic venous disease were graded by the same physician (OSC) according to 2 classification systems, both developed by the American Venous Forum (Appendix 1, http://links.lww.com/MD/A482). The first was the descriptive clinical, etiologic, anatomical, and by pathophysiological (CEAP) classification, which was revised in 2004, and the latter was the venous clinical severity scoring (VCSS) which had been developed as a complementary to the first scheme in 2000 and was revised in 2010. CEAP, there were 8 classes designated as C0 (no visible or palpable signs of venous disease); C1 (telangiectasies or reticular veins); C2 (varicose veins); C3 (edema); C4a (pigmentation); C4b (lipodermatosclerosis); C5 (healed venous ulcer); and C6 (active venous ulcer). In VCSS, there were 10 questions that assessed the intensity of pain, varicose veins, venous edema, skin pigmentation, inflammation, induration, ulcers (number, duration and size), and use of compressive therapy. Each question had 4 possible answers (0: none; 1: mild; 2: moderate; and 3: severe). Points were added to produce a total score ranging between 0 and 30. Total score of CEAP ranged between 0 and 7. The clinical signs in only the more affected leg were considered while grading. Symptoms that could be associated with venous thrombosis, such as itching, cramps, and leg hair loss, were also assessed. Venous claudication was specifically sought using the Edinburgh questionnaire—the revised version of the Rose questionnaire. Severe PTS was defined as CEAP classes 4 through 6.

The institutional review board of the Cerrahpaşa Medical School approved the study and all participants gave informed consent.

Statistical Analysis

Continuous data were expressed as mean and standard deviation (SD). Data with non-normal distribution were expressed as median (interquartile range [IQR]). Comparisons between groups were made by Student t test for normal-distributed continuous variables. Continuous variables with non-normal distribution were compared using Mann–Whitney U test. Categorical variables were compared by the Pearson chi-square test or the Fisher exact test.

Hierarchical cluster analysis was used to identify patterns of venous disease. Tree dendograms that were derived using ϕ correlation coefficient were constituted to visualize cluster patterns in both patient and control groups.

We used univariate and multivariate binary logistic regressions to determine variables that were independently associated with having BS, with control group being accepted as the reference group. To examine relationships between various predictors and severe PTS and venous classification among BS patients, we again used univariate and multivariate binary logistic regressions. Those variables that were found to be associated significantly with univariate analyses were then used to build multiple logistic regression models.

The odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by binary logistic regression models (Enter). All tests were performed using SPSS for Windows, version 20.0, software (IBM SPSS Inc., Chicago, IL).

RESULTS

Demographic and Clinical Characteristics of the Study Population

We studied 78 (71 men, 7 women) BS and 50 (29 men, 21 women) controls with LEVT. As shown in Table 1, BS patients were more likely to be men (91% vs 58%) and had significantly earlier age of onset of thrombosis (32 ± 9 vs 41 ± 13; P < 0.001). Among the BS patients, the median disease duration of BS—from the fulfillment of the criteria to the time of the current study—was 12 (IQR 7–19) years. The median time between BS and thrombosis onset was calculated as 5 years (IQR 2–9 years). Thrombosis duration was calculated as median 5 (IQR 1–10) years for BS and median 7 (IQR 1.3–11.9) months for controls.

Smoking and unemployment were similar in frequency in both groups. These were also true when women were excluded.

Twenty-one (27%) BS subjects had concomitant one or more venous (n = 10) or arterial (n = 11) vascular involvement outside the legs. Venous thrombosis was found in the superior vena cava (n = 3), inferior vena cava (n = 6), dural sinus (n = 5), and hepatic veins (n = 3). Arterial aneurysms were observed in the pulmonary (n = 6), femoral (n = 2), popliteal (n = 1), carotid arteries (n = 1), and abdominal aorta (n = 1). Apart from vascular involvement, 23 (30%) patients had joint, 38 (49%) eye, and 1 patient had parenchymal neurological involvement.

Of the 50 controls with LEVT due to other causes, a possible cause for thrombotic tendency could be identified in 14, such as renal transplantation (n = 1), pregnancy (n = 5), long trip (n = 4), use of oral contraceptives (n = 1), traffic accident (n = 1), and postsurgical intervention (n = 2). Apart from these, 5 patients had been diagnosed with a chronic disease such as rheumatoid arthritis (n = 2), psoriatic arthritis (n = 1), ankylosing spondylitis (n = 1), and chronic hepatitis B (n = 1).

Past and Present History of Drug Use

Seventy-four patients with BS (95%) had been given at least 1 immunosuppressive, which was most commonly...
TABLE 1. Demographic and Clinical Characteristics Among BS Patients and Non-BS Patients With LEVT

|                        | LEVT Due to BS (n=78) | LEVT Due to Other Causes (n=50) | P       |
|------------------------|-----------------------|---------------------------------|---------|
| Males, n (%)           | 71 (91)               | 29 (58)                         | <0.001  |
| Current age, mean ± SD, y | 38.6 ± 10.3           | 42.0 ± 12.5                     | 0.098   |
| Age at thrombosis onset, mean ± SD, y | 32.1 ± 8.9           | 40.8 ± 12.6                     | <0.001  |
| Smoking                |                       |                                 |         |
| Active, n (%)          | 33 (42)               | 20 (40)                         | 0.338   |
| Quit, n (%)            | 21 (27)               | 9 (18)                          |         |
| Never, n (%)           | 24 (31)               | 21 (42)                         |         |
| Unemployment, n (%)    | 29 (37)               | 24 (48)                         | 0.271   |
| Drugs (previously used) |                       |                                 |         |
| Any immunosuppressive, n (%) | 74 (95)            | 3 (6)                           | <0.001  |
| Anticoagulation, n (%)  | 17 (22)               | 49 (98)                         | <0.001  |
| Drugs (currently used)  |                       |                                 |         |
| Any immunosuppressive, n (%) | 50 (64)            | 2 (4)                           | <0.001  |
| Anticoagulation, n (%)  | 6 (8)                 | 44 (84)                         | <0.001  |
| Aspirin, n (%)         | 34 (44)               | 8 (16)                          | 0.001   |

BS = Behçet syndrome, LEVT = lower-extremity vein thrombosis.

azathioprine (AZA) (n = 67, 91%), after being diagnosed with thrombosis. Of these 74 patients, 44 (56%) were also given corticosteroids and 17 (23%) received anticoagulation. The remaining 4 (1 man, 3 women) BS patients had been given colchicine alone. On the contrary, 49 controls (98%) had received anticoagulation.

At the time of the current study, BS patients were using most commonly AZA (64%) and aspirin (44%) less commonly, colchicine (18%), corticosteroids (13%), and anticoagulation (8%). The majority of the controls were, however, using anticoagulants (84%) and aspirin (16%). Similar number of patients were off-treatment in BS (14%) and in the control (8%) groups.

**Doppler USG Results**

**Current Doppler USG Lesions**

Current Doppler USG detected complete recanalization depicting full recovery among 3 (4%) BS patients, whereas 7 (14%) among the controls (P = 0.047). In the remaining, there were similar number of thrombotic lesions (97% vs 95%), partial recanalization (91% vs 91%), and reflux (15% vs 19%). Thrombotic lesions were mostly in the form of chronic thrombosis in both groups (85% vs 81%). Current Doppler studies also showed collateral formation, which was significantly more common among BS patients (31% vs 12%; P = 0.02). Unlike thrombosis, recanalization, and reflux, which are seen in all types of veins, collaterals were specifically observed in the CFV, SFV, and VSM.

**Unilateral/Bilateral Involvement**

The first available Doppler USG had demonstrated that the majority in both groups had unilateral involvement; yet this was significantly more common among the controls (BS: 50/78 [64%] vs controls: 46/50 [92%]; P < 0.001). The current Doppler studies showed that less patients remained with unilateral involvement in both groups, but again this was significantly more common in the control group (BS: 35% vs controls: 61%; P = 0.007).

Anatomical Localization of Lower-extremity Vein Involvement

Figure 1 shows the anatomical locations of the involved veins. Except the crural veins, all deep and superficial veins were significantly more likely to be involved among BS patients. Additionally, there were significantly more patients with both deep and superficial vein (VSM and/or VSP) involvement (n = 78, 72%), as compared with the controls (n = 20, 40%; P < 0.001). The total number of veins involved per patient was significantly higher among BS patients (6.05 ± 3.86 vs 3.82 ± 2.55; P = 0.004).

The probability of having iliac vein involvement in any case was calculated as 27% (95% CI 18–38) for BS and 12% (95% CI 6–24) for controls. In case of CFV involvement, this probability went up to 47% (95% CI 33–61) for BS and to 26% (95% CI 13–46) for controls.

**Variables Strongly Associated with Having BS**

According to the multivariate logistic regression testing, variables associated with having BS were defined as being male (OR 6.8) and younger than ≤35 years of age at the onset of thrombosis (OR 4.1), and having bilateral femoral veins (CFV, SFV, and DFV) (OR 6.8) and VSM involvement (OR 4.0) (Table 2).

**Cluster Analysis of Veins**

In BS, there was almost a symmetrical order in the cluster dendograms, in that venous involvement tended to be contiguous on either side (Fig. 2). CFV, DFV, and SFV, and further iliac vein formed a cluster on the right side. Later on, this cluster was joined by the cluster formed by PV and crural veins, again on the right side. This was similarly duplicated on the left side in a symmetrical pattern. On the contrary, superficial veins (VSM and VSP) clustered always in a symmetrical pattern.

In the control group, however, the associations were disordered (Fig. 3).
Clinical Assessment of Severity

Signs and symptoms assessed with the VCSS classification, CEAP grading, and the frequency of venous claudication are shown in Table 3.

VCSS Classification

Almost all elements used to calculate the VCSS such as pain, varicose veins, hyperpigmentation, inflammation, induration, and active ulcers were significantly more frequent among the BS patients. Whereas leg edema was similar in frequency in both groups, elastic stocking use was significantly more frequent in the control group. Finally, total VCSS score was significantly higher in the BS group. Symptoms unrelated with the VCSS were also assessed: leg hair loss was more (35% vs 14%; P < 0.001), whereas cramping was less common (30% vs 50%; P = 0.019) among BS patients. The frequency of itching was comparable in both groups (35% vs 34%).

Venous clinical severity scoring and CEAP scores were significantly correlated with each other (Spearman r = 0.776, P < 0.0001).

CEAP Grading: Post-thrombotic Syndrome

Behcet syndrome patients had more severe CEAP grades, and the frequency of patients with severe PTS (CEAP ≥4) was significantly higher in the BS group (51% [40/78] vs 8% [4/50]; P < 0.0001). These were also true after adjusting for age and sex (data not shown). It has to be noted that thrombosis duration among BS patients (median 5 years) was substantially longer than that among controls (median 8 months). Therefore, to adjust for thrombosis duration in both groups, only those with thrombosis duration of ≤1 year were analysed. The frequency of PTS was again found to be significantly higher among BS patients (30% [5/17] vs 8% [3/40]; P = 0.045).

Venous Claudication

One-third of the patients with BS, whereas 12% of the controls complained from venous claudication (P = 0.01). This was also true when 4 BS patients with peripheral arterial aneurysms were excluded (23/74, 31% vs 6/50, 12%; P = 0.017). When only those with thrombosis duration of ≤1 year were analyzed, the frequency of venous claudication was again higher in BS, albeit not significant (24% [4/17] vs 12.5% [5/40]; P = 0.428).

Clinical and Ultrasonographic Parameters Associated with Severe PTS and Venous Claudication in BS

As shown in Table 4, having a thrombosis duration of more than ≥5 years (OR 3.3), having bilateral femoral vein (CFV, SFV, and DFV) involvement (OR 3.4), and using no anticoagulation along with immunosuppressive treatment when thrombosis was first diagnosed (OR 3.8) were found to be associated independently with severe PTS.

Multiple regression analyses revealed that venous claudication was significantly associated with having thrombosis duration of less than 5 years, and bilateral femoral vein (CFV, SFV, and DFV) involvement and bilateral VSM involvement (Table 4). Using anticoagulation did not affect the presence or absence of claudication.

The associates of severity could not be calculated in the control group, since there were a few patients with severe PTS or venous claudication.

Differences Between Sexes

We also noted that the female patients with BS had significantly less severe VCSS (2.4 ± 2.2 vs 6.9 ± 5.1; P = 0.023) and CEAP grades (1.7 ± 2.1 vs 3.9 ± 2.3; P = 0.018), and had significant involvement in crural veins (OR 4.3, 95% CI 1.7–10.8, P = 0.002) and bilateral VSM involvement (OR 3.9, 95% CI 1.2–12.0, P = 0.02).

Differences Between Sexes

We also noted that the female patients with BS had significantly less severe VCSS (2.4 ± 2.2 vs 6.9 ± 5.1; P = 0.023) and CEAP grades (1.7 ± 2.1 vs 3.9 ± 2.3; P = 0.018), and had

---

**TABLE 2. Multivariate Logistic Regression Testing for Variables Associated With Lower-extremity Vein Thrombosis Due to Behcet Syndrome**

| Factor Predictor                        | OR  | 95% CI       | P    |
|-----------------------------------------|-----|--------------|------|
| Male sex                                | 7.2 | 2.3–22.8     | 0.001|
| Being ≤35 years of age at the onset of thrombosis | 4.3 | 1.7–10.8     | 0.002|
| Bilateral CFV, SFV, and DFV involvement | 6.0 | 1.2–30.3     | 0.029|
| Bilateral VSM involvement               | 3.9 | 1.2–12.0     | 0.020|

CFV = common femoral vein, CI = confidence intervals, DFV = deep femoral vein, OR = odds ratio, SFV = superficial femoral vein, VSM = vena saphena magna.
significantly lower number of thrombotic veins (2.4 ± 2.7 vs 4.8 ± 2.5; P = 0.020). On the contrary, among controls, men and women were similar with regard to severity scores (VCSS: 4.3 ± 4.0 vs 4.5 ± 2.2, respectively; P = 0.87; CEAP: 1.7 ± 1.7 vs 1.6 ± 1.2, respectively; P = 0.79) and number of involved veins (3.1 ± 2.0 vs 3.5 ± 2.6; P = 0.48).

**DISCUSSION**

In this cross-sectional study, we evaluated the pattern of venous distribution and the clinical impact of LEVT associated with BS and controls. With a controlled study, we are now able to describe a list of clinical and radiological characteristics of LEVT that might be rather specific for BS. Being male and having young age of onset at thrombosis, and having bilateral involvement of deep proximal (CFV, SFV, and DFV) and superficial veins (VSM) were found to be strongly associated with having LEVT associated with BS.

Certain well described features of LEVT due to BS were also noted in this study: LEVT in BS usually occurs within 5 years of disease onset, affects mostly proximal part of the lower extremity venous system similar to that seen in the general population, and is frequently associated with other types of vascular disease.5, 17–21

Our cluster analyses showed that the pattern of venous involvement in BS was contiguous and symmetric in both legs. Starting usually from the CFV, it progresses to both the proximal and the distal veins, affecting deep and superficial veins together, with less affinity for crural veins. In the control patients, however, thrombosis was most commonly unilateral; the combination of deep and superficial vein involvement was less common: consequently, the total number of involved veins was significantly less and the pattern of venous distribution was disorganized.

In addition to the contiguous and symmetric pattern, we observed that there was less complete recanalization and more frequent collateral formation among BS patients compared with controls, suggesting a chronic relapsing course and probably related to that a more obliteratorive and diffuse thrombotic activity. In fact, it could be quite possible that all these distinctive ultrasonographic and clinical characteristics that we find in these patients may simply result from the relapsing course, unique to this syndrome. Moreover, as we and others have previously reported, there is an increased tendency to form collaterals in both venous and arterial side in BS.22–24

In line with the radiological indication of a severe disease, clinical elements of the chronic venous disease were also commonly present in BS. About half of the BS patients showed signs of severe PTS, and one-third suffered from venous claudication, whereas these complications were present in 8% and 12%, respectively, in the control group. It is known that PTS may develop in 20% to 50% of patients after LEVT in the general population.7–10 However, severe PTS was seen in less than 5% in 387 patients with acute DVT, in a 24-month prospective survey.25 In another survey including 355 consecutive patients, it was less than 10% after 8 years of follow-up.26
Determinants of PTS in the general population were venous thrombosis of the common femoral or iliac vein, a higher body mass index, previous ipsilateral venous thrombosis, older age, and female sex. In our survey, however, while bilateral femoral vein involvement was equally important for PTS in BS, young age of onset and male sex were the other determinants for PTS.

We manage BS patients with LEVT differently than those with other causes: immunosuppressive agents are the mainstay of treatment, whereas anticoagulation in addition to immunosuppressives is seldom used, as was the case among the patients we describe here. We have the following reasons to support this approach:

1. The information gathered from our radiologists who do the USG studies routinely and that from the vascular surgeons who routinely perform aneurysms or occlusion operations tell us that thrombus in BS develops as a complication to underlying vasculitis; with relapses, the thrombotic vein evolves into a dense, fibrotic structure, posing little risk for emboli.

2. Pulmonary embolism is indeed extremely rare in post mortem series and according to our group’s clinical experience of almost 40 years. In a very recent thorax computed tomography (CT) study among 49 BS patients with new LEVT, we did not see a single scan showing pulmonary emboli. On the contrary, pulmonary artery thrombus (PAT) that we usually see in BS develops in situ and is manifested as a clinical form of pulmonary artery involvement similar to pulmonary artery aneurysms that requires intensive immunosuppression. Additionally, as we have previously demonstrated before, V/Q scintigraphic changes persist in PAT due to BS in contrast to what is observed in pulmonary emboli in which these changes tend to resolve.

3. Considering the strong association between pulmonary artery involvement and LEVT, there is a risk of massive hemoptysis with anticoagulation. Because of the intensive collateral formation, this risk may still persist during the remission period.

4. Finally, a recent large survey and two others found no additional benefit in terms of thrombotic relapse rate of anticoagulation used in combination with immunosuppressives, compared with immunosuppressives alone.

On the other hand, in the current survey, we were surprised to note that additional anticoagulation was associated with less PTS. While this finding is based on a small subgroup and is subject to limitations of a retrospective design, such as the possibility of those patients having been started on anticoagulants by the referring physicians because of PTS, about which we do not have formal data, it surely points to the long time voiced need of a properly conducted randomized controlled trial of the role of anticoagulation in venous disease in BS. A further consideration is that some elements of the PTS observed in BS might not just be the simple result of the occlusion of the medium to large veins in BS. A possible contribution of the smaller vessels (both venules and arterioles) in the skin may
also play a role in the formation of PTS associated with BS. We are unaware of any related published work.

Finally, venous claudication, we believe, is as much as important as PTS; however, it is being underestimated while evaluating the clinical impact of chronic venous disease. In a recent study, including an almost different cohort, we used a standardized treadmill exercise challenge, similar to that used for the investigation of peripheral arterial disease to evaluate the frequency and severity of venous claudication among BS patients with LEVT and age, and sex-matched healthy controls. While 34% of the BS patients with LEVT described venous claudication according to the questionnaire, 21% complained from claudication during the treadmill test and 10% had to stop the treadmill before the scheduled time. Determinants of venous claudication in the current survey were bilateral femoral involvement, and superficial vein thrombosis and shorter duration of thrombosis. The latter findings suggest that this symptom is somewhat an early symptom and that may disappear or be relieved in time probably once collaterals are formed. It has to be noted that unlike PTS, the frequency of venous claudication did not differ between those who received anticoagulation and those who did not. As LEVT occurs mostly among young men in BS—the potentially productive and active fraction of the population—the clinical and social consequences of this problem such as unemployment, working disability, impairment of quality of life, and depressive mood disorders would be inevitable. We suggest that venous claudication should be included in the routine clinical assessment of vascular disease in BS.

Our study had some limitations. We did not look at the interobserver and intraobserver variability of Doppler USG measurements. We did not study those patients and controls with only venous insufficiency. Doppler USG could not be an optimum tool for iliac vein evaluation in some patients. Finally, we could not match BS patients and controls for duration of thrombosis. On the contrary, we now think that this would be quite difficult, given the obvious differences of disease course between the two forms of LEVT: the considerably shorter thrombosis duration observed in the control group (median 7 months), contrasted with that observed among the BS patients.

### Table 3. Signs and Symptoms Associated With VCSS, CEAP grading, severe PTS, and Venous Claudication

|                      | LEVT Due to BS (n = 78) | LEVT Due to Other Causes (n = 50) | P     |
|----------------------|------------------------|----------------------------------|-------|
| VCSS variables       |                        |                                  |       |
| Pain, n (%)          | 59 (76)                | 29 (58)                          | 0.036 |
| Varicose veins, n (%)| 53 (68)                | 21 (42)                          | 0.004 |
| Leg edema, n (%)     | 46 (59)                | 23 (46)                          | 0.151 |
| Hyperpigmentation, n (%)| 43 (55) | 8 (16)                          | <0.001|
| Inflammation, n (%)  | 18 (23)                | 4 (8)                            | 0.031 |
| Induration, n (%)    | 24 (31)                | 1 (2)                            | <0.001|
| Active ulcer, n (%)  | 10 (11.5)              | 1 (2)                            | 0.049 |
| Compressive therapy, n (%)| 30 (39) | 30 (60)                          | 0.017 |
| Total VCSS score, mean ± SD | 6.5 ± 5.0 | 4.4 ± 3.4                      | 0.005 |
| CEAP classification  |                        |                                  | <0.001|
| C0                   | 8 (10)                 | 12 (24)                          |       |
| C1                   | 9 (11.5)               | 16 (32)                          |       |
| C2                   | 12 (15)                | 8 (16)                           |       |
| C3                   | 9 (11.5)               | 10 (20)                          |       |
| C4                   | 13 (16.5)              | 3 (6)                            |       |
| C5                   | 17 (23)                | 0                                |       |
| C6                   | 10 (11.5)              | 1 (2)                            |       |
| Severe post-thrombotic syndrome (CEAP 4–6), n (%) | 40 (51) | 4 (8) | 0.001 |
| Venous claudication, n (%) | 25 (32) | 6 (12) | 0.01  |

BS = Behcet syndrome, CEAP = clinical, etiologic, anatomical, and by pathophysiological classification, LEVT = lower-extremity vein thrombosis, PTS = post-thrombotic syndrome, VCSS = venous clinical severity score.

### Table 4. Multivariate Logistic Regression Analyses for Variables Associated With Severe Post-thrombotic Syndrome and Claudication in BS

| Factor Predictor                              | Severe Post-thrombotic Syndrome | Venous Claudication |
|-----------------------------------------------|----------------------------------|---------------------|
|                                               | OR 95% CI            | P       | OR 95% CI            | P       |
| Thrombosis duration                           |                        |         |                      |         |
| of more than ≥5 years                         | 3.3                   | 1.2–9.2 | 0.022               | –       |
| of less than <5 years                         | –                    | –       | 16.9                 | 3.4–83.2 | 0.001 |
| Bilateral CFV, SFV, and DFV involvement       | 3.4                   | 1.0–11.5| 0.044               | 7.6     | 1.7–33.8 | 0.007 |
| Bilateral VSM involvement                     | 1.3                   | 0.4–3.9 | 0.670               | 4.6     | 1.2–18.6 | 0.030 |
| Using no anticoagulation along with immunosuppressive treatment at the onset of thrombosis | 3.8                   | 1.04–14.1| 0.043              | 1.4     | 0.3–6.3 | 0.692 |

BS = Behcet syndrome, CFV = common femoral vein, CI = confidence interval, DFV = deep femoral vein, OR = odds ratio, SFV = superficial femoral vein, VSM = vena saphena magna.
limitation, especially considering those patients with extensive bophylic factors in our patients. This omission could also be a limitation, especially considering those patients with extensive recurrent LEVT.

CONCLUSIONS

Lower-extremity vein thrombosis associated with BS has some distinctive demographic and clinical characteristics when compared to LEVT due to other causes or idiopathic LEVT. It occurs mostly among young men, affects deep and superficial lower-extremity veins often together, and tends to be contiguous and bilateral. There is a more severe disease course with half of the patients suffering from severe PTS and one-third from venous claudication.

REFERENCES

1. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60–76.
2. Melikoglu M, Kural-Seyahi E, Tasciyar K, Yazici H. The unique features of vasculitis in Behcet’s syndrome. Clin Rev Allergy Immunol. 2008;35:40–46.
3. Tasciyar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H. Vascular involvement in Behcet’s syndrome: a retrospective analysis of associations and the time course. Rheumatology (Oxford). 2014;53:2018–2022.
4. Seyahi E, Yurdakul S. Behcet’s syndrome and thrombosis. Mediterr J Hematol Infect Dis. 2011;3:e2011026.
5. Ugurlu S, Seyahi E, Yazici H. Prevalence of angina, myocardial infarction and intermittent claudication assessed by Rose Questionnaire among patients with Behcet’s syndrome. Rheumatology (Oxford). 2008;47:472–475.
6. Ugurlu S, Seyahi E, Oktay V, et al. Venous claudication in Behcet’s disease. J Vasc Surg. 2015;62:698–703.e1.
7. Bergan JJ, Schmid-Schönbein GW, Smith PD, Nicolaides AN, Boisseeau MR, Eklof B. Chronic venous disease. N Engl J Med. 2006;355:488–498.
8. Meissner MH, Gloviczki P, Bergan J, et al. Primary chronic venous disorders. J Vasc Surg. 2007;46 (Suppl S):S45–S67S.
9. Saadon M, Stanbys G. Post-thrombotic syndrome: prevention is better than cure. Phlebology Suppl. 2010;25 (Suppl 1):14–19.
10. Kahn SR. The post thrombotic syndrome. Thromb Res. (127 Suppl 3):2011:S89–92.
11. International Study Group for Behcet’s Disease. Criteria for diagnosis of Behcet’s disease. Lancet. 1990;335:1078–1080.
12. Eklof B, Rutherford RB, Bergan JJ, et al., American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004;40:1248–1252.
13. Rutherford RB, Padberg FT Jr, Comerota AJ, Kistner RL, Meissner MH, Moneta GL. Venous severity scoring: An adjunct to venous outcome assessment. J Vasc Surg. 2000;31:1307–1312.
14. Vasquez MA, Rabe E, McLafferty RB, et al., American Venous Forum Ad Hoc Outcomes Working Group. Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. J Vasc Surg. 2010;52:1387–1396.
15. Leng GC, Fowkes FG. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol. 1992;45:1101–1109.
16. Kolbach DN, Neumann HA, Prins MH. Definition of the post-thrombotic syndrome, differences between existing classifications. Eur J Vasc Endovasc Surg. 2005;30:404–414.
17. Tömé A, Aoun N, El-Rassi B, Ghayad E. Vascular manifestations of Behcet’s disease. Eighteen cases among 140 patients. Joint Bone Spine. 2003;70:384–389.
18. Sarica-Kucukoglu R, Akdag-Kose A, Kayabali M, et al. Vascular involvement in Behcet’s disease: a retrospective analysis of 2319 cases. Int J Dermatol. 2006;45:919–921.
19. Dişgün N, Ateş A, Aydınlağ OT, Demir Ö, Ölmez Ü. Characteristics of vascular involvement in Behcet’s disease. Scand J Rheumatol. 2006;35:65–68.
20. Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS. Treatment of venous thrombosis associated with Behcet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol. 2008;27:201–205.
21. Chae EJ, Do KH, Seo JB, et al. Radiologic and clinical findings of Behcet disease: comprehensive review of multisystemic involvement. Radiographics. 2008;28:e31.
22. Temizöz O, Gencellen H, Yekeler E, Demir MK, Uńlu E, Ozdemir H. CT-angiographic demonstration of hepatic collateral pathways due to superior vena cava obstruction in Behcet disease. Diagn Interv Radiol. 2010;16:302–305.
23. Tuzun H, Seyahi E, Arslan C, Hamuryudan V, Besirli K, Yazici H. Management and prognosis of nonpulmonary large arterial disease in patients with Behcet disease. J Vasc Surg. 2012;55:157–163.
24. Seyahi E, Caglar E, Ugurlu S, et al. An outcome survey of 43 patients with Budd-Chiari syndrome due to Behcet’s syndrome followed up at a single, dedicated center. Semin Arthritis Rheum. 2015;44:602–609.
25. Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med. 2008;149:698–707.
26. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1–7.
27. Lakhanpal S, Tani K, Lie JT, Katoh K, Ishigatsubo Y, Ohokubo T. Pathologic features of Behcet’s syndrome: a review of Japanese autopsy registry data. Hum Pathol. 1985;16:790–795.
28. Seyahi E, Cebi Olgun D, Ugurlu S, et al. A CT evaluation of pulmonary and cardiac lesions in Behcet disease patients with Behcet disease. J Vasc Surg. 2012;55:157–163.
29. Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Behcet disease: a series of 47 patients. Medicine (Baltimore). 2012;91:35–48.
30. Desbois AC, Wechsler B, Resche-Rigon M, et al. Immunosuppres- sants reduce venous thrombosis relapse in Behcet’s disease. Arthritis Rheum. 2012;64:2753–2760.
31. Alihaz-Onfer F, Karadeniz A, Yilmaz S, et al. Behcet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Medicine (Baltimore). 2015;94:e494.
32. Espinosa G, Font J, Tassies D, et al. Vascular involvement in Behcet’s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002;112:37–43.

33. Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Behcet’s disease. Ann Rheum Dis. 2004;63:1445–1449.

34. Lee YJ, Kang SW, Yang JI, et al. Coagulation parameters and plasma total homocysteine levels in Behcet’s disease. Thromb Res. 2002;106:19–24.

35. Mader R, Ziv M, Adawi M, et al. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behcet’s disease. J Rheumatol. 1999;26:2404–2408.